For research use only. Not for therapeutic Use.
Faldaprevir（Cat No.:I006759）is an antiviral drug primarily used in the treatment of chronic hepatitis C, acting as a potent, selective inhibitor of the hepatitis C virus (HCV) NS3/4A protease. By inhibiting this enzyme, Faldaprevir prevents the replication of the virus, leading to a reduction in viral load and improvement in liver function. It is often used in combination with other antiviral agents as part of a direct-acting antiviral regimen. Clinical trials have shown its efficacy in improving sustained virologic response rates in HCV-infected patients, particularly in genotype 1 infections.
| Catalog Number | I006759 |
| CAS Number | 801283-95-4 |
| Synonyms | Faldaprevir; BI-201335; BI 201335; BI201335.;(1R,2S)-1-((2S,4R)-4-((8-bromo-2-(2-isobutyramidothiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-1-((S)-2-(((cyclopentyloxy)carbonyl)amino)-3,3-dimethylbutanoyl)pyrrolidine-2-carboxamido)-2-vinylcyclopropane-1-c |
| Molecular Formula | C40H49BrN6O9S |
| Purity | ≥95% |
| Target | Metabolic Enzyme/Protease |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | (1R,2S)-1-[[(2S,4R)-4-[8-bromo-7-methoxy-2-[2-(2-methylpropanoylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-1-[(2S)-2-(cyclopentyloxycarbonylamino)-3,3-dimethylbutanoyl]pyrrolidine-2-carbonyl]amino]-2-ethenylcyclopropane-1-carboxylic acid |
| InChI | InChI=1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1 |
| InChIKey | LLGDPTDZOVKFDU-XUHJSTDZSA-N |
| SMILES | CC(C)C(=O)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3Br)OC)C(=C2)O[C@@H]4C[C@H](N(C4)C(=O)[C@H](C(C)(C)C)NC(=O)OC5CCCC5)C(=O)N[C@@]6(C[C@H]6C=C)C(=O)O |
| Reference | </br>1:Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study. Huang F, Marzin K, Koenen R, Kammerer KP, Strelkowa N, Elgadi M, Quinson AM, Haertter S.J Clin Pharmacol. 2017 May 17. doi: 10.1002/jcph.931. [Epub ahead of print] PMID: 28513969 </br>2:HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. Sarrazin C, Manns M, Calleja JL, Garcia-Samaniego J, Forns X, Kaste R, Bai X, Wu J, Stern JO.PLoS One. 2016 Dec 28;11(12):e0168544. doi: 10.1371/journal.pone.0168544. eCollection 2016. PMID: 28030579 Free PMC Article</br>3:HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection. Sarrazin C, Castelli F, Andreone P, Buti M, Colombo M, Pol S, Calinas F, Puoti M, Olveira A, Shiffman M, Stern JO, Kukolj G, Roehrle M, Aslanyan S, Deng Q, Vinisko R, Mensa FJ, Nelson DR.Clin Exp Gastroenterol. 2016 Nov 24;9:351-363. eCollection 2016. PMID: 27920566 Free PMC Article</br>4:Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir. Meeprasert A, Hannongbua S, Kungwan N, Rungrotmongkol T.Mol Biosyst. 2016 Nov 15;12(12):3666-3673. PMID: 27731877 </br>5:Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir. Berger KL, Sarrazin C, Nelson DR, Scherer J, Sha N, Marquis M, Côté-Martin A, Vinisko R, Stern JO, Mensa FJ, Kukolj G.PLoS One. 2016 Aug 5;11(8):e0160668. doi: 10.1371/journal.pone.0160668. eCollection 2016. PMID: 27494410 Free PMC Article</br>6:Structure Elucidation of Poly-Faldaprevir: Polymer Backbone Solved Using Solid-State and Solution Nuclear Magnetic Resonance Spectroscopy. Gonnella NC, Busacca CA, Zhang L, Saha A, Wu JP, Li G, Davis M, Offerdahl T, Jones PJ, Herfurth L, Reddig T, Wagner K, Niemann M, Werthmann U, Grupe J, Roos H, Reckzügel G, Ding A.J Pharm Sci. 2016 Jun;105(6):1881-90. doi: 10.1016/j.xphs.2016.03.017. PMID: 27238486 </br>7:Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection. Nishiguchi S, Urano Y, Suzaki K, Taniguchi A, Scherer J, Berger KL, Quinson AM, Stern JO, Omata M.Hepatol Res. 2017 Mar;47(3):E142-E151. doi: 10.1111/hepr.12741. Epub 2016 Aug 10. PMID: 27153246 </br>8:Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. Zeuzem S, Mantry P, Soriano V, Buynak RJ, Dufour JF, Pockros PJ, Wright D, Angus P, Buti M, Stern JO, Kadus W, Vinisko R, Böcher W, Mensa FJ.Eur J Gastroenterol Hepatol. 2016 Aug;28(8):923-6. doi: 10.1097/MEG.0000000000000649. PMID: 27140229 </br>9:Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, Böcher WO, Ferenci P.Ann Hepatol. 2016 May-Jun;15(3):333-49. doi: 10.5604/16652681.1198803. PMID: 27049487 Free Article</br>10:Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants. Wu J, Gießmann T, Lang B, Elgadi M, Huang F.J Pharm Pharmacol. 2016 Apr;68(4):459-66. doi: 10.1111/jphp.12538. Epub 2016 Mar 28. PMID: 27019158 |
